Abstract
As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Current Molecular Medicine
Title: RAGE in Diabetic Nephropathy
Volume: 7 Issue: 8
Author(s): Hiroshi Yamamoto, Takuo Watanabe, Yasuhiko Yamamoto, Hideto Yonekura, Seiichi Munesue, Ai Harashima, Kazuyo Ooe, Sharmin Hossain, Hidehito Saito and Naho Murakami
Affiliation:
Keywords: iNOS transgenic mice, endothelial cells, aminoguanidine, RAGE gene, diabetic nephropathy
Abstract: As is diabetes itself, diabetic angiopathy is a multi-factorial disease. Advanced glycation endproducts (AGE) cause vascular cell derangement characteristic of diabetes, and this is mainly mediated by their interaction with receptor for AGE (RAGE). When made diabetic, RAGE-overexpressing transgenic mice exhibited exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. On the other hand, RAGE-deficient animals showed amelioration of diabetic nephropathy. Accordingly, AGE and RAGE should be regarded as environmental and cellular accounts and as a potential therapeutic target for diabetic nephropathy. In effect, substances that inhibit the formation of AGE, break preformed AGE, change metabolic flows away from glycation, antagonize RAGE, and capture RAGE ligands have been proven as effective remedies against this life-threatening disease.
Export Options
About this article
Cite this article as:
Yamamoto Hiroshi, Watanabe Takuo, Yamamoto Yasuhiko, Yonekura Hideto, Munesue Seiichi, Harashima Ai, Ooe Kazuyo, Hossain Sharmin, Saito Hidehito and Murakami Naho, RAGE in Diabetic Nephropathy, Current Molecular Medicine 2007; 7 (8) . https://dx.doi.org/10.2174/156652407783220769
DOI https://dx.doi.org/10.2174/156652407783220769 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Microglia in Alzheimer's Disease: The Good, the Bad and the Ugly
Current Alzheimer Research Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein Aggregation and Its Consequences for Human Disease
Protein & Peptide Letters Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Current Vascular Pharmacology Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Connexins, Diabetes and the Metabolic Syndrome
Current Protein & Peptide Science Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics New Perspectives for the Diagnosis of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Adrenomedullin Expression in Alzheimer's Brain
Current Alzheimer Research Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Are Anti-Angiogenic Drugs Useful in Neurodegenerative Disorders?
CNS & Neurological Disorders - Drug Targets A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer’s Disease
Current Drug Targets Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Importance of ABC Transporters in Drug Development
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry